Drug intelligence / Profile preview

IBI-355

Development stage: Phase 1
Lead developer: Suzhou Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI-355 is a monoclonal antibody drug candidate developed by Innovent Biologics. It targets the CD40 ligand (CD40L), acting as a modulator or inhibitor of this immune co-stimulatory molecule. The primary mechanism of action involves modulation of the CD40-CD40L pathway, which plays a key role in immune activation and is implicated in various autoimmune diseases. IBI-355 is being investigated for the treatment of autoimmune disorders, with current clinical trials focusing on primary Sjögren's syndrome and systemic lupus erythematosus. As of late 2024, it is in Phase 1 clinical development in China[1][2][3][7].

Targets

CD40LG (CD40 ligand extracellular domain)

Beyond the preview

Go deeper on IBI-355.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI-355.

Explore the full profile